ANVS - Annovis Bio, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD

Annovis Bio, Inc.

1055 Westlakes Drive
Suite 300
Berwyn, PA 19312
United States

Full Time Employees2

Key Executives

NameTitlePayExercisedYear Born
Dr. Maria L. MacCecchiniFounder, CEO, Pres & Director120kN/A1951
Mr. Jeffrey B. McGroarty CPAChief Financial OfficerN/AN/A1969
Dr. Jeffrey L. CummingsChief Medical Officer & Member of Scientific Advisory BoardN/AN/A1950
Dr. William C. MobleyChief Scientific Advisor & Member of Scientific Advisory BoardN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Annovis Bio, Inc., a clinical stage drug platform company, focuses on developing compounds to address neurodegeneration. The company's lead compound is ANVS-401, which is in Phase 2a clinical trials for the treatment of chronic neurodegenerative diseases, such as Down syndrome, Alzheimer's disease (AD), and Parkinson's disease. It is also developing ANVS-301, a compound in Phase 1 clinical trials to increase cognitive capability in later stages of AD and dementia; and ANVS-405, which is in preclinical study for protecting the brain after traumatic brain injury and/or stroke. Annovis Bio, Inc. was formerly known as QR Pharma, Inc. and changed its name to Annovis Bio, Inc. in March 2019. The company was founded in 2008 and is based in Berwyn, Pennsylvania.

Corporate Governance

Annovis Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.